MedImmune LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1987-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://medimmune.com
Clinical Trials
292
Active:26
Completed:233
Trial Phases
5 Phases
Phase 1:147
Phase 2:81
Phase 3:25
+2 more phases
Drug Approvals
6
CANADA:3
Clinical Trials
Distribution across different clinical trial phases (270 trials with phase data)• Click on a phase to view related trials
Phase 1
147 (54.4%)Phase 2
81 (30.0%)Phase 3
25 (9.3%)Phase 4
15 (5.6%)Not Applicable
1 (0.4%)phase_2_3
1 (0.4%)A Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Combination with Axitinib in Subjects with Advanced Renal Cell Carcinoma
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- AstraZeneca AB
- Target Recruit Count
- 93
- Registration Number
- 2023-509604-15-00
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
🇪🇸Institut Catala D'oncologia, L'hospitalet De Llobregat, Spain
🇪🇸Hospital Del Mar, Barcelona, Spain
IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.
Phase 1
Completed
- Conditions
- Advanced Solid Tumors
- First Posted Date
- 2020-02-07
- Last Posted Date
- 2022-08-15
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 57
- Registration Number
- NCT04261075
- Locations
- 🇨🇭
Research Site, Lausanne, Switzerland
Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC
Phase 2
Withdrawn
- Conditions
- Microsatellite-stable Colorectal Cancer
- Interventions
- Drug: Standard of Care - mFOLFOX6Drug: E1 - mFOLFOX and durvalumabDrug: E2 - mFOLFOX6, durvalumab and oleclumabDrug: E3 - mFOLFOX6, durvalumab and monalizumab
- First Posted Date
- 2019-10-30
- Last Posted Date
- 2020-09-21
- Lead Sponsor
- MedImmune LLC
- Registration Number
- NCT04145193
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 36
- Registration Number
- NCT04091373
- Locations
- 🇺🇸
Research Site, Daytona Beach, Florida, United States
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
Phase 1
Active, not recruiting
- Conditions
- Metastatic Microsatellite-stable Colorectal Cancer
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2025-07-28
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 61
- Registration Number
- NCT04068610
- Locations
- 🇪🇸
Research Site, Madrid, Spain
- Prev
- 1
- 2
- 3
- 4
- 5
- 54
- Next
News
No news found